XML 44 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
11. Segment Information
 9 Months Ended
Sep. 30, 2012
Segment Reporting [Abstract]  
Segment Information
11.SEGMENT INFORMATION

Information regarding industry segments for the three months ended September 30, 2012 and 2011 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2012
$
167.0

 
$
328.4

 
$
3.3

 
2011
$
171.5

 
$
341.3

 
$
3.7

 
 
 
 
 
 
 
Segment profit
2012
$
6.4

 
$
47.0

 
$
—

 
2011
$
12.5

 
$
49.5

 
$
0.5


Information regarding industry segments for the nine months ended September 30, 2012 and 2011 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2012
$
484.2

 
$
999.6

 
$
11.6

 
2011
$
495.9

 
$
1,016.5

 
$
10.9

 
 
 
 
 
 
 
Segment profit
2012
$
7.8

 
$
148.1

 
$
1.9

 
2011
$
25.6

 
$
144.1

 
$
1.1




Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment.  The following reconciles total segment profit to consolidated income before taxes (in millions):

 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2012
 
2011
 
2012
 
2011
Total segment profit
$
53.4

 
$
62.5

 
$
157.8

 
$
170.9

Foreign exchange losses, net
(0.4
)
 
(6.3
)
 
(3.5
)
 
(12.1
)
Net corporate operating, interest and other expense not allocated to segments
(1.1
)
 
(0.9
)
 
(3.4
)
 
(2.8
)
Other income (expense), net
1.5

 
0.5

 
14.7

 
5.9

Consolidated income before taxes
$
53.4

 
$
55.8

 
$
165.6

 
$
161.9